JNJ
JOHNSON & JOHNSON
NYSE · Healthcare · Drug Manufacturers - General · US
$253.79
−0.69%Aug 10, 2026, 05:32 UTC
Kaken Pharmaceutical reported first-quarter (April-June) operating profit of 10.902 billion yen, a significant increase from 14 million yen a year earlier, boosted by a $70 million milestone payment from Johnson & Johnson under a licensing agreement.
Source:Aug 4, 2026, 19:23 UTC
Johnson & Johnson spent $25 billion on share repurchases over the past five years.
Source:Aug 4, 2026, 19:23 UTC
Johnson & Johnson paid $60 billion in dividends to shareholders over the past five years.
Source:Aug 4, 2026, 12:45 UTC
Johnson & Johnson announced that Tom Kavanagh will succeed Jennifer Taubert as Executive Vice President and Worldwide Chairman of the Innovative Medicine segment.
Aug 3, 2026, 23:59 UTC
The trial of former New Mexico state lawmaker Sheryl Williams Stapleton began in U.S. District Court in Albuquerque, where she faces 37 criminal counts including conspiracy, bribery, money laundering, and mail fraud for allegedly approving about $3.2 million in payments to Robotics Management Learning Systems and receiving about $1.1 million in kickbacks.
Aug 3, 2026, 16:21 UTC
Johnson & Johnson reported strong Q2 2026 oncology performance, with sales boosted by Darzalex, Erleada, and newer cancer drugs.
Source:Jul 31, 2026, 18:19 UTC
Johnson & Johnson announced two biotech acquisitions totaling $3.5 billion to expand its oncology pipeline.
Source:Jul 30, 2026, 12:30 UTC
Johnson & Johnson announced that the U.S. FDA granted Priority Review to its supplemental Biologics License Application for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma.
Source:Jul 29, 2026, 21:46 UTC
Sail Biomedicines announced a strategic collaboration with Johnson & Johnson to develop In Vivo CAR-T therapies for immune-mediated diseases.
Source:Jul 29, 2026, 21:42 UTC
Johnson & Johnson completed the acquisition of Firefly Bio to advance next-generation oncology innovation.
Jul 29, 2026, 21:31 UTC
Johnson & Johnson entered into a strategic agreement with Sail Biomedicines, obtaining an exclusive option to acquire the company for $2.58 billion and concurrently making an equity investment, with an initial total payment of $785 million.
Jul 25, 2026, 14:00 UTC
Johnson & Johnson MedTech unveiled its Ottava surgical robot after receiving FDA de novo authorization.
Source:Jul 23, 2026, 13:58 UTC
Johnson & Johnson announced positive late-stage trial results for its combination treatment Tecvayli and Talvey for relapsed or refractory multiple myeloma, showing an 89% reduction in risk of disease progression or death.
Source:Jul 22, 2026, 11:00 UTC
The U.S. Food and Drug Administration granted De Novo marketing authorization for Johnson & Johnson's OTTAVA Robotic Surgical System.
Jul 15, 2026, 16:09 UTC
Johnson & Johnson reported progress toward a table-integrated robotic surgical system.
Source:Jul 15, 2026, 16:09 UTC
Johnson & Johnson launched AI-powered imaging and mapping capabilities for electrophysiology.
Source:Jul 15, 2026, 16:09 UTC
Johnson & Johnson reported early momentum for a drug releasing system for bladder cancer treatment.
Source:Jul 15, 2026, 10:25 UTC
Johnson & Johnson's Board of Directors declared a quarterly cash dividend of $1.34 per share for the third quarter of 2026, payable on September 8, 2026 to shareholders of record on August 25, 2026.
Source:Jul 8, 2026, 11:45 UTC
Johnson & Johnson announced that the U.S. FDA approved its Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
Source:Jul 4, 2026, 07:51 UTC
Stayfree launched Stayfree Xpert XL, a new sanitary pad with a three-in-one protection system, to expand its menstrual hygiene portfolio.
Source:Jun 30, 2026, 00:00 UTC
Matthew Pauls was appointed as a Class I director of Palvella Therapeutics, Inc.
Jun 29, 2026, 16:40 UTC
J&J received a positive CHMP opinion for expanded use of Tecvayli in combination with Darzalex SC for relapsed/refractory multiple myeloma.
Source:Jun 25, 2026, 09:00 UTC
Johnson & Johnson made its Dual Energy THERMOCOOL SMARTTOUCH SF Platform available in Europe, advancing cardiac ablation technology.
Source:Jun 15, 2026, 10:00 UTC
Johnson & Johnson invested more than $1 billion to build a new distribution facility and expand manufacturing, packaging, and distribution capabilities for its Vision operations in Jacksonville, Florida.
Jun 14, 2026, 07:15 UTC
Legend Biotech announced first clinical proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed/refractory B-cell Non-Hodgkin Lymphoma.
Jun 11, 2026, 11:45 UTC
Johnson & Johnson expanded U.S. availability of its TECNIS PureSee IOL, an advanced lens option for cataract surgeons and patients.
Source:Jun 11, 2026, 06:03 UTC
Johnson & Johnson presented pivotal Phase 2/3 study results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia at EHA 2026 in Stockholm.
Source:Jun 10, 2026, 15:22 UTC
A Los Angeles jury awarded $32 million to the family of Maria Lozano, finding Johnson & Johnson liable for her mesothelioma from asbestos-contaminated talc.
Source:Jun 8, 2026, 12:00 UTC
Johnson & Johnson has agreed to acquire Firefly Bio, Inc. for $1 billion in cash.
Jun 6, 2026, 01:56 UTC
A California jury reached a defense verdict in favor of Johnson & Johnson in the second bellwether ovarian cancer talcum powder trial in Los Angeles.
Jun 3, 2026, 04:04 UTC
Johnson & Johnson announced that nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, with results presented at a conference.
Source:Jun 2, 2026, 10:30 UTC
LISTERINE introduced a new range of mouthwash intensities, including Extra Mild, available nationwide as of June 2, 2026.